Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/22/2021 09/23/2021 09/24/2021 09/27/2021 09/28/2021 Date
72.04(c) 73.05(c) 73.61(c) 73.36(c) 73.32 Last
9 028 738 12 813 485 14 714 660 8 630 563 11 836 180 Volume
+0.10% +1.40% +0.77% -0.34% -0.05% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 46 881 M - -
Net income 2021 12 645 M - -
Net Debt 2021 15 254 M - -
P/E ratio 2021 16,0x
Yield 2021 3,54%
Sales 2022 50 668 M - -
Net income 2022 15 523 M - -
Net Debt 2022 10 724 M - -
P/E ratio 2022 12,5x
Yield 2022 3,83%
Capitalization 186 B 186 B -
EV / Sales 2021 4,28x
EV / Sales 2022 3,87x
Nbr of Employees 73 500
Free-Float 70,7%
More Financials
Company
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and... 
Sector
Pharmaceuticals
Calendar
10/28Earnings Release
More about the company
Ratings of Merck & Co., Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about MERCK & CO., INC.
11:08aGLOBAL MARKETS LIVE : Airbus, Merck, Geely, Toyota, Activision Blizzard...
09:09aNovartis Lining Up More Potent COVID-19 Antiviral Pills Rivaling Merck, Pfizer
MT
09:08aI-Mab Secures Approval to Conduct Phase 2 Trial of Enoblituzumab Combo Therapy for Soli..
MT
09:05aWALL STREET STOCK EXCHANGE : Is inflation still transitionary?
08:11aMERCK : Announces KEYTRUDA (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) i..
AQ
06:46aMERCK : to Hold Third-Quarter 2021 Sales and Earnings Conference Call on October 28
BU
04:47aMERCK : Reportedly in Advanced Talks to Buy Acceleron Pharma
MT
09/27MERCK : Said to Buy Acceleron Pharma in Rare Diseases Boost
MT
09/27Merck Reportedly in Advanced Talks to Buy Acceleron Pharma
CI
09/27MERCK : Announces KEYTRUDA« (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) ..
BU
09/27MERCK : Says Keytruda Met Primary Endpoint of Overall Survival in Patients With Liver Canc..
MT
09/27MERCK : LYNPARZA (olaparib) in combination with abiraterone significantly delayed disease ..
AQ
09/27MERCK : LYNPARZA (olaparib) in Combination With Abiraterone Significantly Delayed Disease ..
AQ
09/27Merck Announces Keytruda« (Pembrolizumab) Met Primary Endpoint of Overall Survival (OS)..
CI
09/27Merck Says Keytruda Liver Cancer Study Meets Objective
DJ
More news
News in other languages on MERCK & CO., INC.
04:13pMÄRKTE USA/Zinssorgen treiben Anleger in die Flucht
12:27pMÄRKTE USA/Anleger suchen aus Zinsangst das Weite
09:53aMÄRKTE USA/Anhaltender Renditeanstieg belastet - Nasdaq minus 1,6 %
09:09aNovartis prépare des pilules antivirales COVID-19 plus puissantes pour rivaliser avec M..
08:49aLes valeurs à suivre aujourd'hui à Wall Street Mardi 28 septembre 2021
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 73,32 $
Average target price 93,42 $
Spread / Average Target 27,4%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-10.32%185 702
JOHNSON & JOHNSON3.45%429 542
ROCHE HOLDING AG9.24%319 352
PFIZER, INC.18.36%244 283
NOVO NORDISK A/S48.08%227 557
ELI LILLY AND COMPANY31.25%205 250